Eli Lilly Licenses ADDF’s SpeechDx Dataset for Alzheimer’s Research

Eli Lilly licensed the Alzheimer's Drug Discovery Foundation's SpeechDx dataset, a large longitudinal speech and biomarker resource, to advance research on speech as a tool for Alzheimer's diagnosis and monitoring. SpeechDx is the largest harmonized dataset covering the Alzheimer's continuum and is also licensed by Siemens Healthineers and Callyope. Lilly aims to improve early detection and intervention for Alzheimer's disease using this data.